Amgen said it has filed for an offering of two mln common shares, including one mln to be sold outside the U.S. It said U.S. underwriters will be led by PaineWebber Group Inc <PWJ> and <Montgomery Securities> and PaineWebber will lead the overseas underwriters. Proceeds will be used to fund capital spending and working capital requirements on the commercialization and further development of Amgen products. 